Immunoscintigraphy in intraocular malignant melanoma

K. Scheidhauer; A. Markl; G. Leinsinger; E. Moser; O. F. Scheiffarth; K. G. Riedel; T. S. Schaal; F. H. Stefani; U. Schumacher

doi:10.1097/00006231-198809000-00010

Immunoscintigraphy in intraocular malignant melanoma

K. Scheidhauer, A. Markl, G. Leinsinger, E. Moser, O. F. Scheiffarth, K. G. Riedel, T. S. Schaal, F. H. Stefani, U. Schumacher

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Immunoscintigraphy of malignant tumours has become an encouraging tool in nuclear medicine. Early diagnosis of small lesions is mandatory for successful cancer therapy. The scintigraphic detectability of small lesions (< 1 cm in diameter) by immunoscintigraphy is shown in 39 patients suffering from ocular tumours (37 malignant choroidal melanoma, two benign choroidal naevi) using⁹⁹Tc^m-labelled F(ab')₂fragments of the anti-melanoma monoclonal antibody 225.28S; this antibody recognizes the high molecular weight melanoma-associated antigen. No adverse effects were observed. In terms of true-positive results, single photon emission computed tomography (SPECT) proved to be superior to planar scans (73% versus 41% true-positive results).

Original language	English
Pages (from-to)	669-678
Number of pages	10
Journal	Nuclear Medicine Communications
Volume	9
Issue number	9
DOIs	https://doi.org/10.1097/00006231-198809000-00010
State	Published - Sep 1988
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00006231-198809000-00010

Cite this

@article{63736280107e42d2ba06962dcaf27f1e,

title = "Immunoscintigraphy in intraocular malignant melanoma",

abstract = "Immunoscintigraphy of malignant tumours has become an encouraging tool in nuclear medicine. Early diagnosis of small lesions is mandatory for successful cancer therapy. The scintigraphic detectability of small lesions (< 1 cm in diameter) by immunoscintigraphy is shown in 39 patients suffering from ocular tumours (37 malignant choroidal melanoma, two benign choroidal naevi) using99Tcm-labelled F(ab')2fragments of the anti-melanoma monoclonal antibody 225.28S; this antibody recognizes the high molecular weight melanoma-associated antigen. No adverse effects were observed. In terms of true-positive results, single photon emission computed tomography (SPECT) proved to be superior to planar scans (73% versus 41% true-positive results).",

author = "K. Scheidhauer and A. Markl and G. Leinsinger and E. Moser and Scheiffarth, {O. F.} and Riedel, {K. G.} and Schaal, {T. S.} and Stefani, {F. H.} and U. Schumacher",

year = "1988",

month = sep,

doi = "10.1097/00006231-198809000-00010",

language = "English",

volume = "9",

pages = "669--678",

journal = "Nuclear Medicine Communications",

issn = "0143-3636",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "9",

}

TY - JOUR

T1 - Immunoscintigraphy in intraocular malignant melanoma

AU - Scheidhauer, K.

AU - Markl, A.

AU - Leinsinger, G.

AU - Moser, E.

AU - Scheiffarth, O. F.

AU - Riedel, K. G.

AU - Schaal, T. S.

AU - Stefani, F. H.

AU - Schumacher, U.

PY - 1988/9

Y1 - 1988/9

N2 - Immunoscintigraphy of malignant tumours has become an encouraging tool in nuclear medicine. Early diagnosis of small lesions is mandatory for successful cancer therapy. The scintigraphic detectability of small lesions (< 1 cm in diameter) by immunoscintigraphy is shown in 39 patients suffering from ocular tumours (37 malignant choroidal melanoma, two benign choroidal naevi) using99Tcm-labelled F(ab')2fragments of the anti-melanoma monoclonal antibody 225.28S; this antibody recognizes the high molecular weight melanoma-associated antigen. No adverse effects were observed. In terms of true-positive results, single photon emission computed tomography (SPECT) proved to be superior to planar scans (73% versus 41% true-positive results).

AB - Immunoscintigraphy of malignant tumours has become an encouraging tool in nuclear medicine. Early diagnosis of small lesions is mandatory for successful cancer therapy. The scintigraphic detectability of small lesions (< 1 cm in diameter) by immunoscintigraphy is shown in 39 patients suffering from ocular tumours (37 malignant choroidal melanoma, two benign choroidal naevi) using99Tcm-labelled F(ab')2fragments of the anti-melanoma monoclonal antibody 225.28S; this antibody recognizes the high molecular weight melanoma-associated antigen. No adverse effects were observed. In terms of true-positive results, single photon emission computed tomography (SPECT) proved to be superior to planar scans (73% versus 41% true-positive results).

UR - http://www.scopus.com/inward/record.url?scp=0023752159&partnerID=8YFLogxK

U2 - 10.1097/00006231-198809000-00010

DO - 10.1097/00006231-198809000-00010

M3 - Article

C2 - 3263596

AN - SCOPUS:0023752159

SN - 0143-3636

VL - 9

SP - 669

EP - 678

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

IS - 9

ER -

Immunoscintigraphy in intraocular malignant melanoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this